Reports Q2 revenue $2.4B, consensus $2.34B. “We continued our momentum in the second quarter, delivering our fifth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA, underscoring the strength of our product and geographic footprint and reinforcing our strategy. We remain focused on advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive growth globally. I’m proud of the hard work and accomplishments of our team, who work tirelessly to improve the health of patients worldwide,” said Thomas J. Appio, Chief Executive Officer, Bausch Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- BHC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bausch Health holders pay ‘price’ for ‘irresponsible journalism,’ says Jefferies
- Bausch Health price target lowered to $7 from $8 at Truist
- Bausch Health Refutes Bankruptcy Rumors
- Bausch Health off lows after denying bankruptcy rumors, remains down 17%